Premium
Elevated serum levels of p105 erbB‐2 in patients with advanced‐stage prostatic adenocarcinoma
Author(s) -
Myers Russell B.,
Brown David,
Oelschlager Denise K.,
Waterbor John W.,
Marshall M. Ernest,
Srivastava Sudhir,
Stockard Cecil R.,
Urban Donald A.,
Grizzle William E.
Publication year - 1996
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19961021)69:5<398::aid-ijc8>3.0.co;2-0
Subject(s) - medicine , stage (stratigraphy) , prostate , hyperplasia , adenocarcinoma , prostate cancer , immunohistochemistry , urology , gastroenterology , cancer , pathology , oncology , biology , paleontology
Expression of a truncated or extracellular form (p105 erbB‐2 ) of p185 erbB‐2 has been demonstrated in the sera of breast cancer patients. We examined the levels of p105 erbB‐2 in the sera of patients with various stages of prostatic adenocarcinoma, in patients with benign prostatic hyperplasia (BPH) and in a series of control male patients hospitalized for illnesses unrelated to the prostate. p105 erbB‐2 levels did not differ between the controls and BPH patients or between these groups and patients with stage A, B or C adenocarcinomas. In contrast, serum p105 erbB‐2 levels of patients with stage D adenocarcinomas were significantly elevated when compared with either control or BPH patients. There was no correlation between PSA and p105 erbB‐2 levels among controls, patients with BPH or patients with prostate cancer. Patients with poorly differentiated tumors (combined Gleason score >7) or moderately differentiated tumors (combined Gleason score 5–7) had higher p105 erbB‐2 levels as compared to patients with well‐differentiated tumors (combined Gleason score <5), though this difference was not statistically significant. There was no correlation between serum p105 erbB‐2 levels and p185 erbB‐2 expression in malignant tissue, as determined by immunohistochemistry. However, patients with moderate to strong expression of p185 erbB‐2 within the adenocarcinomas were approximately 4 times more likely to demonstrate elevated serum p105 erbB‐2 levels as compared with patients with low expression of p185 erbB‐2 . © 1996 Wiley‐Liss, Inc.